Genmab maintains 2026 revenue guidance, forecasts 19% growth at midpoint
GMAB•Genmab maintained 2026 revenue guidance of $4.33 billion to $4.53 billion, implying 19% growth at the midpoint. It forecasts adjusted operating profit of $1.07 billion to $1.39 billion.
1. 2026 outlook
Genmab maintained its 2026 revenue guidance of $4.33 billion to $4.53 billion, implying 19% growth at the midpoint. Adjusted operating profit is forecast at $1.07 billion to $1.39 billion, while adjusted operating expenses are projected at $2.81 billion to $2.95 billion.
2. Investment priorities
The projected expenses reflect accelerated late-stage development and launch preparations. Genmab cited EPKINLY growth and continued momentum across its royalty portfolio as support for the revenue outlook, and said investment focuses on petosemtamab and Rina-S, with multiple potential launches expected in 2027.
